Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials

DOI10.1007/s10260-020-00537-3zbMath1480.62224OpenAlexW3044325711MaRDI QIDQ2059113

Valeria Sambucini

Publication date: 13 December 2021

Published in: Statistical Methods and Applications (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1007/s10260-020-00537-3

zbMATH Keywords

Bayesian approachposterior predictive probabilitiesefficacy and toxicity outcomesmultinomial-Dirichlet distributionsingle-arm phase II trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Unnamed Item
• Bayesian two-stage design for phase II clinical trials with switching hypothesis tests
• Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Bivariate Sequential Designs for Phase II Trials
• On construction of single‐arm two‐stage designs with consideration of both response and toxicity
• What Does Objective Mean in a Dirichlet‐multinomial Process?